exceptional service across specialties

The journey for patients with complex, hard-to-diagnose diseases can be long and challenging. Many spend years moving from one specialist to another before receiving a diagnosis, and managing treatment and related difficulties can be a daily struggle.

As a specialty pharmacy focused on supporting patients with these complex conditions, we are committed to guiding you through every stage of theat journey, both clinically and administratively to help you achieve the best possible outcomes. Out Therapy Care Teams are extensively trained in each condition we support, allowing us to tailor our approach to meet the unique needs of every patient. Learn more about the conditions and therapies we support below.

Asthma & Allergy

Asthma is a long term condition causing inflammation to the airways and making it difficult to breathe.

Bleeding Disorders

There are several bleeding disorders such as Hemophilia, Von Willebrand disease, and several clotting factors deficiencies.

Hepatitis B

Chronic Hepatitis B is a virus transmitted by bodily fluids that can lead to serious liver damage.

Hepatitis C

Hepatitis C is an infection caused by a bloodborne virus affecting the liver.

HIV

HIV is a serious viral infection that attacks the body’s immune system and if left untreated can seriously impair the body’s ability to fight off infections.

Inflammatory Bowel Disease

IBD is inflammation of the GI tract manifesting in either Crohn’s disease or Ulcerative colitis.

Multiple Sclerosis

MS is a very complex disease affecting the central nervous system.

Oncology

Oncology involves several different types of cancer and can affect multiple areas of the body.

Pulmonary Hypertension

PH is a rare condition in which high blood pressure occurs specifically in the lungs.

Rheumatology

Many rheumatologic diseases are autimmune conditions often times affecting the joints.

Sickle Cell Disease

Sickle cell disease is caused by a hereditary condition affecting the red blood cells.

Transplant

Transplant refers to the life-saving organ transplantation of a healthy organ to another individual.

Search by Drug

Search by Condition or Specialty

  • cinacalcet

    • Drug: cinacalcet

    • Manufacturer: misc

    • Route of Administration: Oral

    • Site of Care: Outpatient
    • Approved Indication:

      • secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis
      • hypercalcemia in adult patients with parathyroid carcinoma
      • hypercalcemia in adult patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels but who are unable to undergo parathyroidectomy
    • Disease: hypercalcemia, secondary hyperparathyroidism
    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology, Immunology

    • Enrollment Form Link: N/A

    • Phone Number: N/A
    • Fax Number: N/A
    • Product Website: N/A

  • Creon

    • Drug: Creon (pancrelipase)
    • Manufacturer: AbbVie

    • Route of Administration: Oral

    • Site of Care: Outpatient
    • Approved Indication: treatment of exocrine pancreatic insufficiency in adult and pediatric patients
    • Disease: exocrine pancreatic insufficiency
    • Therapeutic Area: Gastroenterology
    • Enrollment Form Link: patientsupport.creoninfo.com/enroll
    • Phone Number: 1-844-ONCREON (1-844-662-7366)
    • Fax Number: 1-866-573-0750
    • Product Website: creoninfo.com

  • Cresemba

    • Drug: Cresemba (isavuconazonium sulfate)
    • Manufacturer: Astellas

    • Route of Administration: Oral

    • Site of Care: Outpatient
    • Approved Indication: treatment of invasive aspergillosis and invasive mucormycosis in adults and pediatric patients 6 years of age and older who weigh at least 16 kilograms
    • Disease: invasive aspergillosis, mucormycosis
    • Therapeutic Area: Infectious disease
    • Enrollment Form Link: astellaspharmasupportsolutions.com/cresemba/forms
    • Phone Number: 1-800-477-6472

    • Fax Number: 1-866-317-6235

    • Product Website: cresemba.com

  • Cyltezo

    • Drug: Cyltezo (adalimumab-adbm)
    • Manufacturer: Boehringer Ingelheim

    • Route of Administration: Subcutaneous

    • Site of Care: Outpatient
    • Approved Indication:

      • reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
      • reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
      • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
      • reducing signs and symptoms in adult patients with active ankylosing spondylitis
      • treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older
      • treatment of moderately to severely active ulcerative colitis in adult patients
      • treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
      • treatment of moderate to severe hidradenitis suppurativa in adult patients
      • treatment of non-infectious intermediate, posterior, and panuveitis in adult patients
    • Disease: ankylosing spondylitis, Crohn’s disease, hidradenitis suppurativa, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, uveitis
    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology
    • Enrollment Form Link: patient.boehringer-ingelheim.com/us/products/cyltezo/self-enroll
    • Phone Number: 1-833-295-8396
    • Fax Number: 1-866-648-4577
    • Product Website: cyltezo.com

  • Dificid

    • Drug: Dificid (fidaxomicin)
    • Manufacturer: Merck

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication: treatment of Clostridium difficile-associated diarrhea in adults and pediatric patients 6 months of age and older

    • Disease: C. difficile diarrhea

    • Therapeutic Area: Infectious disease

    • Enrollment Form Link: merckhelps.com/Dificid
    • Phone Number: 800-727-5400
    • Fax Number: 915-921-8539
    • Product Website: dificid.com

  • Dupixent

    • Drug: Dupixent (dupilumab)
    • Manufacturer: Sanofi | Regeneron

    • Route of Administration: Subcutaneous

    • Site of Care: Outpatient

    • Approved Indication:

        • treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
        • add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma
        • add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps
        • treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kilograms, with eosinophilic esophagitis
        • treatment of adult patients with prurigo nodularis
        • add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease and an eosinophilic phenotype
        • treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment
    • Disease: asthma, atopic dermatitis, chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyp, chronic spontaneous urticaria, eosinophilic esophagitis, prurigo nodularis
    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology
    • Enrollment Form Link: www.dupixent.com/patient-support
    • Phone Number: 1-844-387-4936
    • Fax Number: 1-844-387-9370
    • Product Website: dupixent.com

  • entecavir

    • Drug: entecavir
    • Manufacturer: misc

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication: treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease

    • Disease: chronic viral hepatitis B
    • Therapeutic Area: Infectious disease, Gastroenterology, Hepatology

    • Enrollment Form Link: N/A

    • Phone Number: N/A
    • Fax Number: N/A
    • Product Website: N/A

  • Entyvio

    • Drug: Entyvio (vedolizumab)
    • Manufacturer: Takeda

    • Route of Administration: Intravenous, Subcutaneous

    • Site of Care: Outpatient

    • Approved Indication:

      • treatment of moderately to severely active ulcerative colitis
      • treatment of moderately to severely active Crohn’s disease
    • Disease: Crohn’s disease, ulcerative colitis
    • Therapeutic Area: Gastroenterology
    • Enrollment Form Link: www.entyvio.com/patient-support
    • Phone Number: 1-855-ENTYVIO (1-855-368-9846)
    • Fax Number: 1-877-488-6814

    • Product Website: entyvio.com

  • Envarsus XR

    • Drug: Envarsus XR (tacrolimus extended-release)
    • Manufacturer: Veloxis Pharmaceuticals

    • Route of Administration: Oral

    • Site of Care: Outpatient

    • Approved Indication:

      • prophylaxis of organ rejection in de novo kidney transplant patients in combination with other immunosuppressants
      • prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants
    • Disease: solid organ transplant

    • Therapeutic Area: Infectious disease

    • Enrollment Form Link: www.envarsusxr.com/resources

    • Phone Number: 1-844-VELOXIS (1-844-835-6947)
    • Fax Number: 844-475-8931

    • Product Website: envarsusxr.com

  • Epclusa

    • Drug: Epclusa (sofosbuvir/velpatasvir)
    • Manufacturer: Gilead

    • Route of Administration: Oral

    • Site of Care: Outpatient
    • Approved Indication: treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis, with compensated cirrhosis, or with decompensated cirrhosis for use in combination with ribavirin
    • Disease: chronic viral hepatitis C
    • Therapeutic Area: Infectious disease, Gastroenterology, Hepatology
    • Enrollment Form Link: epclusa.com/access

    • Phone Number: 1-844-4-EPCLUSA (1-844-437-2587) or 1-855-7-MYPATH (1-855-769-7284)

    • Fax Number: 1-855-298-8700
    • Product Website: epclusa.com